Pacira BioSciences (PCRX) vs Seaport Therapeutics (SPTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pacira BioSciences is the larger company by market cap ($1.45 billion vs $968.1 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCRX | SPTX |
|---|---|---|
| Share price | $36.31 | $18.09 |
| Market cap | $1.45B | $968.10M |
| 1-day change | -0.22% | +0.98% |
| YTD return | +40.61% | — |
| 1-year return | +55.45% | — |
| 5-year return | -31.60% | — |
| P/E ratio (TTM) | 103.74 | — |
| Forward P/E | 10.50 | — |
| EPS (TTM) | $0.35 | $-5.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $726.41M | — |
| Revenue growth (YoY) | +3.63% | — |
| Net income (latest FY) | $7.03M | — |
| Gross margin | 79.39% | — |
| Operating margin | 2.64% | — |
| Net margin | 0.97% | — |
| 52-week high | $36.46 | $28.38 |
| 52-week low | $18.80 | $14.85 |
| Distance from 52-week high | -0.41% | -36.28% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -17.08% | +111.72% |
| Average volume | 1.03M | 182.45K |
| Shares outstanding | 39.91M | 53.53M |
| Employees | 825 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
About Seaport Therapeutics
SPTX stock →Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
PCRX vs SPTX FAQ
Which is bigger, Pacira BioSciences or Seaport Therapeutics?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $968.10M for Seaport Therapeutics (SPTX).
Are Pacira BioSciences and Seaport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.